title: [Hemodynamic, anti-ischemic, metabolic and neurohumoral effects of enoximone (MDL 17,043) in patients with coronary disease].
abstract: The hemodynamic, anti-ischemic, metabolic, and neurohumoral effects of the phosphodiesterase inhibitor enoximone were investigated in 17 patients (mean age 58 +/- 2 years) with coronary heart disease as established by coronary angiography and positive exercise tests after i.v. application of 0.75 mg/kg body weight. Whereas administration of enoximone resulted in a significant increase in heart rate from 75 +/- 17 to 83 +/- 14 per minute (p less than 0.01), exercise heart rate, blood pressure and myocardial oxygen consumption did not change significantly (p greater than 0.05). At rest, enoximone led to a significant decrease of mean right atrial pressure from 5.7 +/- 2.3 to 3.8 +/- 1.2 mm Hg (p less than 0.01). During exercise there was a significant fall in pulmonary pressure (PAm from 40 +/- 7 to 24 +/- 7 mm Hg, p less than 0.001; PCm from 24 +/- 7 to 14 +/- 6 mm Hg, p less than 0.001) caused by preload reduction and concomitant inotropic increase; there was also a significant rise in cardiac output from 12.7 +/- 5 to 13.8 +/- 5 mm Hg (p less than 0.01) and a decrease of ST-segment depression from 1.97 +/- 0.76 to 0.53 +/- 0.51 mm (p less than 0.001). With improved peripheral and probably coronary blood flow, a concomitant decrease of the metabolic ischemic markers was detected during exercise (potassium 4.44 +/- 0.29 vs. 4.31 +/- 0.30 mval, p less than 0.05; lactate 19 +/- 9 vs. 18 +/- 7 mg/dl; pH 7.28 +/- 0.27 vs. 7.36 +/- 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Kerckhoff-Klinik, Max-Planck-Gesellschaft, Bad Nauheim.
authors.forename: V
authors.initials: V
authors.lastname: Mitrovic
authors.forename: M
authors.initials: M
authors.lastname: Schlepper
authors.forename: J
authors.initials: J
authors.lastname: Neuzner
authors.forename: H
authors.initials: H
authors.lastname: Bahavar
authors.forename: M
authors.initials: M
authors.lastname: Volz
authors.forename: H A
authors.initials: HA
authors.lastname: Dieterich
mesh_terms: D000368:Aged; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D003326:Coronary Circulation / Q000187:drug effects; D003327:Coronary Disease / Q000188:drug therapy*; D004562:Electrocardiography; D004734:Energy Metabolism / Q000187:drug effects; D017335:Enoximone; D004837:Epinephrine / Q000097:blood; D005080:Exercise Test; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood
chemical_list: D002316:Cardiotonic Agents; D007093:Imidazoles; D017335:Enoximone; D009638:Norepinephrine; D004837:Epinephrine
vernacular_title: Hämodynamische, antiischämische, metabolische und neurohumorale Effekte von Enoximon (MDL 17,043) bei Patienten mit koronarer Herzkrankheit.